Bicara Therapeutics Current Valuation vs. Shares Outstanding
| BCAX Stock | 20.79 0.17 0.81% |
For Bicara Therapeutics profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Bicara Therapeutics to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Bicara Therapeutics Common utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Bicara Therapeutics's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Bicara Therapeutics Common over time as well as its relative position and ranking within its peers.
Bicara |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Bicara Therapeutics. If investors know Bicara will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Bicara Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (3.75) |
The market value of Bicara Therapeutics is measured differently than its book value, which is the value of Bicara that is recorded on the company's balance sheet. Investors also form their own opinion of Bicara Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Bicara Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Bicara Therapeutics' market value can be influenced by many factors that don't directly affect Bicara Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Bicara Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Bicara Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Bicara Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Bicara Therapeutics Shares Outstanding vs. Current Valuation Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Bicara Therapeutics's current stock value. Our valuation model uses many indicators to compare Bicara Therapeutics value to that of its competitors to determine the firm's financial worth. Bicara Therapeutics Common is rated second in current valuation category among its peers. It also is rated second in shares outstanding category among its peers creating about 0.09 of Shares Outstanding per Current Valuation. The ratio of Current Valuation to Shares Outstanding for Bicara Therapeutics Common is roughly 10.61 . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Bicara Therapeutics' earnings, one of the primary drivers of an investment's value.Bicara Current Valuation vs. Competition
Bicara Therapeutics Common is rated second in current valuation category among its peers. After adjusting for long-term liabilities, total market size of Health Care industry is currently estimated at about 1.62 Billion. Bicara Therapeutics totals roughly 577.25 Million in current valuation claiming about 36% of equities under Health Care industry.
Bicara Shares Outstanding vs. Current Valuation
Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Bicara Therapeutics |
| = | 577.25 M |
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
Outstanding Shares are shares of common stock of a public company that were purchased by investors after they were authorized and issued by the company to the public. Outstanding Shares are typically reported on fully diluted basis, including exotic instruments such as options, or convertibles bonds.
Bicara Therapeutics |
| = | 54.39 M |
Outstanding shares that are stated on company Balance Sheet are used when calculating many important valuation and performance indicators including Return on Equity, Market Cap, EPS and many others.
Bicara Shares Outstanding Comparison
Bicara Therapeutics is currently under evaluation in shares outstanding category among its peers.
Bicara Therapeutics Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Bicara Therapeutics, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Bicara Therapeutics will eventually generate negative long term returns. The profitability progress is the general direction of Bicara Therapeutics' change in net profit over the period of time. It can combine multiple indicators of Bicara Therapeutics, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
| Last Reported | Projected for Next Year | ||
| Net Interest Income | 1.3 M | 663.3 K | |
| Interest Income | 1.3 M | 724.9 K | |
| Operating Income | -39.9 M | -41.9 M | |
| Net Loss | -52 M | -54.6 M | |
| Income Before Tax | -52 M | -54.6 M | |
| Total Other Income Expense Net | -13.4 M | -12.7 M | |
| Net Loss | -52 M | -54.6 M |
Bicara Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Bicara Therapeutics. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Bicara Therapeutics position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Bicara Therapeutics' important profitability drivers and their relationship over time.
Use Bicara Therapeutics in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Bicara Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Bicara Therapeutics will appreciate offsetting losses from the drop in the long position's value.Bicara Therapeutics Pair Trading
Bicara Therapeutics Common Pair Trading Analysis
The ability to find closely correlated positions to Bicara Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Bicara Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Bicara Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Bicara Therapeutics Common to buy it.
The correlation of Bicara Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Bicara Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Bicara Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Bicara Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your Bicara Therapeutics position
In addition to having Bicara Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Money Funds Thematic Idea Now
Money Funds
Funds or Etfs that invest most if their asset in companies from financial sector such as commercial banks, insurance companies, investment funds, and real estate. The Money Funds theme has 34 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Money Funds Theme or any other thematic opportunities.
| View All Next | Launch |
Additional Tools for Bicara Stock Analysis
When running Bicara Therapeutics' price analysis, check to measure Bicara Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bicara Therapeutics is operating at the current time. Most of Bicara Therapeutics' value examination focuses on studying past and present price action to predict the probability of Bicara Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Bicara Therapeutics' price. Additionally, you may evaluate how the addition of Bicara Therapeutics to your portfolios can decrease your overall portfolio volatility.